International update: new findings on promising medications.
Litten
R Z
RZ
National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
D000077443:Acamprosate; D000427:Alcohol Deterrents / Q000009:adverse effects / Q000627:therapeutic use*; D000437:Alcoholism / Q000523:psychology / Q000534:rehabilitation*; D000818:Animals; D002986:Clinical Trials as Topic; D003042:Cocaine; D015897:Comorbidity; D005060:Europe; D006801:Humans; D009271:Naltrexone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000534:rehabilitation; D013654:Taurine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014481:United States
D000427:Alcohol Deterrents; D009292:Narcotic Antagonists; D013654:Taurine; D009271:Naltrexone; D003042:Cocaine; D000077443:Acamprosate; C038981:nalmefene